---

Global Contract Development and Manufacturing Organization (CDMO) Lonza has signed an extension of its partnership with a “major” biopharmaceutical company for the manufacture of antibody-drug conjugates (ADC) at commercial scale.

ADCs are a form of cancer treatment that combines chemotherapy with a targeting antibody.

Through this combination, they are able to deliver effective chemotherapy agents specifically to cancer cells while limiting damage to healthy tissues.

“Offering end-to-end ADC manufacturing services eliminates supply chain complexities and streamlines product delivery at scale. The extension of our collaboration reflects our ability to meet our customers’ needs with operational expertise, innovative solutions, and flexible business models,” stated Christian Morello, Vice President, Head of Bioconjugates, Lonza.

---

READ ALSO: Lonza Secures Long-Term Agreement to Supply Critical Cell Therapy for Sickle Cell Treatment

---

In the agreement, Lonza will provide commercial-scale monoclonal antibody (mAb) manufacturing services for a new ADC therapy.

Additionally, it will enhance the dedicated bioconjugation footprint for the client through the construction of a new bioconjugation suite at Lonza’s Ibex® Biopark in Visp, Switzerland.

The new Visp bioconjugation suite will support the production, handling, and containment of highly potent modalities and will take up about 800 m2 of manufacturing area.

It is anticipated that the new suite would create about 100 additional jobs when it opens in 2027.

Lonza's connection with the customer is further strengthened by the customer-dedicated suite, which already includes an integrated supply of the payload, drug-linker, commercial mAb manufacture, conjugation services, and DP filling for the ADC molecule that targets tumors that are difficult to treat.

---

Did you find this insightful? Subscribe for more.

---